Patent application number | Description | Published |
20100306867 | TRANSGENIC ANIMALS PRODUCING MONOVALENT HUMAN ANTIBODIES AND ANTIBODIES OBTAINABLE FROM THESE ANIMALS - The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods. | 12-02-2010 |
20100325744 | NON-GLYCOSYLATED RECOMBINANT MONOVALENT ANTIBODIES - The present invention provides non-glycosylated monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies. | 12-23-2010 |
20110038869 | MONOCLONAL ANTIBODIES AGAINST CD32B - Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies. | 02-17-2011 |
20110086366 | METHODS FOR ASSESSING THE RISK OF ADVERSE EVENTS UPON TREATMENT WITH IGG4 ANTIBODIES - The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies. | 04-14-2011 |
20130039913 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF - Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins. | 02-14-2013 |
20130189271 | MONOCLONAL ANTIBODIES AGAINST HER2 - Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 07-25-2013 |
20130216548 | MONOCLONAL ANTIBODIES AGAINST C-MET - Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 08-22-2013 |
20140170148 | BISPECIFIC ANTIBODIES AGAINST HER2 - Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed. | 06-19-2014 |
20140170149 | BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3 - Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed. | 06-19-2014 |
20140242075 | ANTIBODY VARIANTS AND USES THEREOF - Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response. | 08-28-2014 |
20140303356 | PRODUCTION OF HETERODIMERIC PROTEINS - The present invention relates to an in vitro method for production of heterodimeric proteins. | 10-09-2014 |
Patent application number | Description | Published |
20100105874 | BISPECIFIC ANTIBODIES AND METHODS FOR PRODUCTION THEREOF - The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention. | 04-29-2010 |
20100166740 | Anti-OX40L antibodies - This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases. | 07-01-2010 |
20100255012 | RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING - Glycosylated monovalent antibodies binding to selected antigens with a low or lacking fucose content, which are capable of inducing antibody dependent cellular cytotoxicity (ADCC) on cells expressing the selected antigens in the presence of effector cells, methods for producing the monovalent antibodies, pharmaceutical compositions comprising such monovalent antibodies and use thereof for different diagnostic and therapeutic applications. | 10-07-2010 |
20100291023 | METHOD FOR EXTENDING THE HALF-LIFE OF EXOGENOUS OR ENDOGENOUS SOLUBLE MOLECULES - The present invention relates to methods for extending the in vivo half-life of an exogenous soluble therapeutic molecule administered to a subject, by administering to said subject the exogenous soluble molecule and a monovalent antibody that binds to the exogenous soluble molecule, as well as method for treating a disease or disorder associated with an insufficient level of an endogenous soluble molecule in a subject, by administering to said subject a monovalent antibody that binds to the endogenous soluble molecule. | 11-18-2010 |
20110070239 | ANTI-OX40L ANTIBODIES - This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C | 03-24-2011 |
20110293607 | Antibody Variants Having Modifications In The Constant Region - The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed. | 12-01-2011 |
20120020952 | METHODS FOR PRODUCING MIXTURES OF ANTIBODIES - The invention relates to a method for producing a mixture comprising two or more different antibodies in a single recombinant host cell. In one embodiment, a mixture of different monovalent antibodies is produced. In another embodiment, a mixture of monovalent and bivalent antibodies is produced. The invention also relates to mixtures of antibodies obtainable by the method of the invention and to light chain sequences that are particularly useful in the method of the invention. | 01-26-2012 |